Patrick Gallagher

Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member of the Board of Directors.

Currently a Senior Managing Director at Laidlaw & Co., Mr. Gallagher is an accomplished Capital Markets executive, advisor, and investor with a distinguished record of success in both public and private markets. His day-to-day duties include frequent interaction with institutional investors, C-level corporate executives, KOL’s and industry thought leaders.

Prior to joining Laidlaw & Co., Mr. Gallagher was a founding partner and CEO of BDR Research Group, LLC., a healthcare-focused management consulting and investment research boutique specialized in providing advisory services for healthcare investors and their portfolio companies. He began his career with positions at investment and research firms Kidder Peabody, PaineWebber, and New Vernon Associates.

Mr. Gallagher’s leadership and strategy initiatives have included business development, go-to-market planning, and execution, and identifying new market opportunities for legacy businesses and product lines at several Biotechnology and Medtech companies, including Cingulate, Athenex (f.k.a. Kinex Pharmaceuticals), BioSig Technologies, Protea Biosciences, and Evermore Global Advisors. Mr. Gallagher earned an MBA from Penn State University and a Bachelor of Arts from the University of Vermont.